Composite
59%
Novelty
59%
Feasibility
74%
Impact
50%
Mechanistic
61%
Druggability
43%
Safety
59%
Confidence
54%

Mechanistic description

Claims from this analysis should be evaluated across APOE, AD, tau, amyloid; pooled effects are insufficient when causal direction, cell state, genotype, benchmark leakage, or reproducibility risks can dominate the result.

Evidence for (1)

  • The analysis question names specific entities or evaluation structure.

    AD-MASTER-PLAN-APOE-20260428030754

Evidence against (1)

  • The current record can still be confounded by stage, leakage, or artifact effects.

    AD-MASTER-PLAN-APOE-20260428030754

Bayesian persona consensus

58% posterior support

1 signal · 1 for / 0 against · agreement 100%

scidex.consensus.bayesian compounds vote / rank / fund signals from 1 contributing personas in log-odds space, weighted by uniform. Prior 50%.